Protein Nanoparticles - PNP
For oral/subcutaneous/pulmonary delivery of hydrophobic drugs, proteins, peptides, genes and vaccine antigens
Conventional Protein Nanoparticles Techniques and their Drawbacks
An ongoing concern in the pharmaceutical and biotechnology industries is the administration of a steady dosage of a therapeutic agent. In the formulation of controlled release therapeutics, it is frequently desirable to disperse the material into very fine, uniform particles. Such particles may then be advantageously incorporated into controlled-release delivery vehicles such as polymeric nanospheres/microspheres, depots or implantable devices, or delivered to the lungs as an aerosol. With proteinaceous therapeutics, the generation of such fine particles is particularly problematic with several drawbacks.
A Solution – The PNP Process
Protein Nanoparticles (PNP) technology platform utilizes the expansive energy of supercritical fluids with or without polar cosolvents (SuperFluids™ [SFS]) to disaggregate or comminute protein crystals and amorphous powders into monodisperse nanoparticles [US Patent].
The PNP process uses SuperFluids™ to form small protein particles without first dissolving the material in a liquid solvent. As such, the target therapeutic retains full activity and is devoid of residual processing chemicals such as solvents, salts or surfactants. The energy necessary for the size reduction is derived from a rapid depressurization of the SuperFluids™. The low temperature generated by the expansion of the supercritical fluid helps to preserve the chemical integrity of the protein and is an advantage over conventional grinding processes that generate heat.
Benefits/Advantages of the PNP Process
Applications of the PNP Process
Aphios' protein nanoparticles (PNP) process can be used for oral/subcutaneous/pulmonary delivery of hydrophobic drugs such as paclitaxel, camptothecin and betulinic acid, proteins such as insulin, calcitonin and human growth hormone, peptides, genes and vaccine antigens for anthrax, HIV and influenza.
Contact us if you are interested in conducting a feasibility study and/or establishing a research and development partnership.